About Cambium Biomaterials
Cambium Biomaterials is a private company based in El Segundo, California. It has reported $119,743,487 raised in three offerings on Form D since September 2021. Its chief executive is Simon Waddington.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Nov 18, 2025 | Dec 4, 2025 | $94,366,494of $101.3M target | 33 | $2.8M | EquityRule 506(b) | Form D ↗ |
| Nov 8, 2023 | Nov 14, 2023 | $17,364,116of $19.9M target | 16 | $1.0M | EquityRule 506(b) | Form D ↗ |
| Sep 2, 2021 | Sep 17, 2021 | $8,012,877of $28.0M target | 3 | $2.6M | EquityRule 506(b) | Form D ↗ |
| Total, three offerings | $119,743,487 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Cambium Biomaterials's Form D filed Dec 4, 2025.
CP
Christopher Pederson
Director
BS
Brett Schneider
Director
TG
Tim Gardner
Executive officer
SH
Stephan Herrera
Executive officer
SW
Simon Waddington
Chief Executive Officer and director
JG
James Griffin
Executive officer
NM
Nic Madren
Executive officer
Earlier filings also listed Eliot Pence (executive officer, last listed Nov 2023) and Andrew Guenthner (executive officer, last listed Sep 2021).